CP 248
Latest Information Update: 26 Jan 2017
At a glance
- Originator Cell Pathways
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Cyclic GMP phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bronchopulmonary dysplasia; Cancer; Lung cancer
Most Recent Events
- 25 Jan 2017 Discontinued - Preclinical for Bronchopulmonary dysplasia in USA (Inhalation)
- 25 Jan 2017 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 25 Jan 2017 Discontinued - Preclinical for Lung cancer in USA (Inhalation)